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MaOBJECTIVES This study assessed the predictive value of coronary artery calcium (CAC) score for cerebrovascular
events (CVE) in an asymptomatic multiethnic cohort.
BACKGROUND The CAC score, a measure of atherosclerotic burden, has been shown to improve prediction of coronary
heart disease events. However, the predictive value of CAC for CVE is unclear.
METHODS CAC was measured at baseline examination of participants (N ¼ 6,779) of MESA (Multi-Ethnic Study of
Atherosclerosis) and then followed for an average of 9.5  2.4 years for the diagnosis of incident CVE, deﬁned as
all strokes or transient ischemic attacks.
RESULTS During the follow-up, 234 (3.5%) adjudicated CVE occurred. In Kaplan-Meier analysis, the presence of CAC
was associated with a lower CVE event-free survival versus the absence of CAC (log-rank chi-square: 59.8, p < 0.0001).
Log-transformed CAC was associated with increased risk for CVE after adjusting for age, sex, race/ethnicity, body mass
index, systolic and diastolic blood pressure, total cholesterol, high-density lipoprotein cholesterol, cigarette smoking
status, blood pressure medication use, statin use, and interim atrial ﬁbrillation (hazard ratio [HR]: 1.13 [95% conﬁdence
interval (CI): 1.07 to 1.20], p < 0.0001). The American College of Cardiology/American Heart Association–recommended
CAC cutoff was also an independent predictor of CVE and strokes (HR: 1.70 [95% CI: 1.24 to 2.35], p ¼ 0.001, and HR:
1.59 [95% CI: 1.11 to 2.27], p ¼ 0.01, respectively). CAC was an independent predictor of CVE when analysis was stratiﬁed
by sex or race/ethnicity and improved discrimination for CVE when added to the full model (c-statistic: 0.744 vs. 0.755).
CAC also improved the discriminative ability of the Framingham stroke risk score for CVE.
CONCLUSIONS CAC is an independent predictor of CVE and improves the discrimination afforded by current stroke risk
factors or the Framingham stroke risk score for incident CVE in an initially asymptomatic multiethnic adult cohort. (J Am
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AB BR E V I A T I O N S
AND ACRONYM S
CAC = coronary artery calcium
CVE = cerebrovascular events
TIA = transient ischemic attack
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1109prediction in the general population based on these
data (7).
The recent American College of Cardiology (ACC)/
American Heart Association (AHA) guidelines for risk
prediction adopted a new composite: atherosclerotic
cardiovascular disease (ASCVD), which includes cor-
onary death, nonfatal myocardial infarction, and fatal
and nonfatal stroke (8). The new AHA/ACC ASCVD
risk score does not consider current subclinical
atherosclerosis measures. Given persuasive data on
the improvement of discrimination for CVD by
subclinical atherosclerotic measures (4,5) and theSEE PAGE 1116similarity of the constituents of the pooled ASCVD
risk prediction tool with the Framingham risk score
(8,9), there are ongoing efforts to improve the risk
prediction afforded by the new pooled ASCVD risk
tool with these subclinical atherosclerotic measures
in the general population. However, adding subclin-
ical atheroscleroticmeasures to the newpooled ASCVD
risk tool would only make sense if these measures
were associated with strokes. A recent publication
from the HNR (Heinz Nixdorf Recall) study with a
larger number of strokes than that of prior published
data (1–3) showed an independent association be-
tween CAC and strokes in low- to intermediate-risk
Caucasian subjects (10). However, the racial homoge-
neity of the HNR cohort limits its external validity.
Thus, the association between CAC and strokes in
the general population remains unclear.
In this report, we examined the relationship of
CAC measured during the baseline examination to
adjudicated cerebrovascular events (CVE) in partici-
pants of the MESA (Multi-Ethnic Study of Athero-
sclerosis) over a 10-year follow-up.
METHODS
STUDY POPULAT ION AND DATA COLLECT ION .
A detailed description of the study design for MESA
has been published (11). In brief, MESA is a cohort
study that began in July 2000 to investigate the
prevalence, correlates, and progression of subclinical
CVD. At baseline, the cohort included 6,814 women
and men age 45 to 84 years recruited from 6 U.S.
communities (Baltimore, Maryland; Chicago, Illinois;
Forsyth County, North Carolina; Los Angeles County,
California; northern Manhattan, New York; and
St. Paul, Minnesota). MESA participants were 38%
white, 28% black, 22% Hispanic, and 12% Chinese.
Individuals with a history of physician-diagnosed
myocardial infarction, angina, heart failure, stroke,
or transient ischemic attack (TIA) or who hadundergone an invasive procedure for CVD
(coronary artery bypass graft, angioplasty,
valve replacement, pacemaker placement, or
other vascular surgeries) were excluded.
Demographics, medical history, and
anthropometric and laboratory data for these
analyses were obtained at the ﬁrst MESA examination
(July 2000 to August 2002). Current smoking was
deﬁned as having smoked a cigarette in the past 30
days. Diabetes mellitus was deﬁned as fasting
glucose $126 mg/100 dl or use of hypoglycemic medi-
cations. Use of antihypertensive and other medica-
tions was based on the review of prescribed
medication containers. Resting blood pressure was
measured 3 times in a seated position, and the average
of the second and third readings was used. Hyperten-
sion was deﬁned as a systolic blood pressure $140
mm Hg, diastolic blood pressure $90 mmHg, or use of
medication prescribed for hypertension. Body mass
index was calculated as weight (kg)/height2 (m2). Total
and high-density lipoprotein cholesterol were
measured from blood samples obtained after a 12-h
fast. Low-density lipoprotein cholesterol was esti-
mated by the Friedewald equation (12). The MESA
study was approved by the institutional review boards
of each study site, and written informed consent was
obtained from all participants.
MEASUREMENT OF CAC SCORE. Details of the MESA
computed tomography (CT) scanning and interpre-
tation methods have been reported by Carr et al.
(13). Scanning centers assessed CAC by noncontrast
cardiac CT with either an electron-beam CT scanner
(Chicago, Illinois; Los Angeles, California; and New
York, New York ﬁeld centers) or a multidetector CT
system (Baltimore, Maryland; Forsyth County, North
Carolina; and St. Paul, Minnesota ﬁeld centers).
Certiﬁed technologists scanned all participants twice
over phantoms of known physical calcium concen-
tration. A radiologist or cardiologist read all CT scans
at a central reading center (Los Angeles Biomedical
Research Institute at Harbor–University of California,
Los Angeles, Torrance, California). We used the mean
Agatston score for the 2 scans in all analyses (14).
Intraobserver and interobserver agreements were
excellent (k ¼ 0.93 and 0.90, respectively).
ASCERTAINMENT OF CVE. Strokes, TIAs, and
other cardiovascular events were adjudicated by a
MESA committee that included cardiologists, physi-
cian epidemiologists, and neurologists. A detailed
description of the adjudication process has been
published (11). For the purposes of this study, we
deﬁned CVE as fatal or nonfatal strokes due to
hemorrhage or infarcts or TIA. TIAs and strokes
TABLE 1 Demograph
Cerebrovascular Even
Age, yrs
Male
Race/ethnicity
Caucasian
Chinese
African American
Hispanic
Body mass index, kg/m
Cholesterol, mg/dl
Total
LDL
HDL
Triglycerides
Cigarette smoking
Never
Former
Current
Diabetes mellitus
Blood pressure, mm Hg
Systolic
Diastolic
Antihypertensive use
Statin use
CAC score, Agatston un
Developed atrial ﬁbrilla
Values are mean  SD, n (
CAC ¼ coronary artery
MESA ¼ Multi-Ethnic Stud
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1110were also used individually as secondary outcomes
for this analysis. Interim incident atrial ﬁbrillation,
which occurred during the follow-up period, was ad-
justed for in the full model as a time-varying covariate.
Interim atrial ﬁbrillation in MESA is a combination
of adjudicated; International Classiﬁcation of Dis-
eases, Ninth Revision code; and self-reported cases.
STATISTICAL ANALYSIS. Demographic and other
characteristics were compared according to cerebro-
vascular event. CAC was introduced into models as
a binary variable (CAC present/absent), as a contin-
uous variable (In [CAC þ 1]), or as 4 categories
(CAC: 0, 0 to 100, >100 to 400, and >400 Agatston
units). Kaplan-Meier and Cox proportional hazards
analyses were used to evaluate the association
between CAC and incident CVE. Among participants
with more than 1 type of event adjudicated during the
follow-up period, the ﬁrst event was used in this
analysis. Covariates entered in models were chosen
on the basis of their association with incident CVE in
the present analyses and in published data. The
covariates include age, sex, race/ethnicity, bodyic Characteristics of MESA Participants With and Without
ts During the Follow-Up Period
No Cerebrovascular Event
(n ¼ 6,545)
Cerebrovascular Event
(n ¼ 234)
61.9  10.2 67.9  9.6
3,089 (47.1) 111 (47.6)
2,526 (38.5) 93 (39.7)
791 (12.0) 12 (5.2)
1,823 (27.7) 69 (29.5)
1,435 (21.8) 60 (21.8)
2 28.3  5.5 28.7  5.1
194.1  35.8 194.1  33.8
117.2  31.5 118.4  30.4
51.1  14.9 48.0  12.5
131.2  89.1 140.8  75.5
3,302 (50.4) 114 (48.9)
2,406 (36.7) 78 (33.5)
846 (12.9) 41 (17.6)
804 (12.3) 52 (22.2)
126.1  21.2 140.0  22.2
71.8  10.2 74.9  11.5
2,144 (32.6) 121 (51.7)
957 (14.8) 31 (13.3)
its 80.8 (0.0–140.7) 289.8 (0.0–313.7)
tion 368 (5.6) 40 (17.1)
%), or median (interquartile range). Mean follow-up was 9.5  2.4 years.
calcium score; HDL ¼ high-density lipoprotein; LDL ¼ low-density lipoprotein;
y of Atherosclerosis.mass index, systolic and diastolic blood pressure,
total cholesterol, high-density lipoprotein, cigarette
smoking status, blood pressure medication use, statin
use, and interim atrial ﬁbrillation that occurred dur-
ing the follow-up period. The full multivariable
model was then stratiﬁed by sex and race/ethnicity.
The preceding analysis was repeated with all strokes
and TIAs as the outcome.
The improvement of discrimination for incident
CVE afforded by the addition of CAC to our full model
was evaluated using the receiver-operating curve
analysis. The Framingham stroke risk score (FSRS)
(15) was calculated for each MESA participant (using
baseline data only) using the following variables: age,
systolic blood pressure, diabetes mellitus, cigarette
smoking, prior CVD, atrial ﬁbrillation, left ventricular
hypertrophy (ECG criteria), and blood pressure med-
ications. No MESA participant had prior CVD or atrial
ﬁbrillation during the baseline examination. The
improvement in discrimination afforded by the
addition of CAC to the FSRS (and also using the con-
stituents in the model) was also assessed using
receiver-operating curve analysis. A 2-tailed value of
p < 0.05 was considered signiﬁcant. All statistical
analyses were performed using SAS version 9.2 (SAS
Institute, Cary, North Carolina).
RESULTS
After a mean of 9.5  2.4 years, 234 (3.5%) adjudicated
CVE (180 strokes and 67 TIAs) were identiﬁed.
Ischemic CVE (cerebral infarcts and TIAs) were
observed in 206 (3.4%) participants, of whom 152
(2.2%) had cerebral infarcts. Participants who devel-
oped a cerebrovascular event were older, had a worse
cardiovascular risk proﬁle, and developed atrial
ﬁbrillation more often (17.1% vs. 5.6%) during the
follow-up period than those who did not have a ce-
rebrovascular event (Table 1). As shown in Table 2,
similar proportions of the participants within each
CAC category had hemorrhagic strokes during the
follow-up period. However, an increased proportion
of participants had cerebral infarcts, TIAs, and atrial
ﬁbrillation with higher CAC category.
CAC AND CEREBROVASCULAR EVENT PREDICTION. In
Kaplan-Meier analyses, participants with CAC present
during the baseline examination had a lower cere-
brovascular event-free survival rate compared with
participants with CAC absent at baseline (log-rank
chi-square: 59.84, p < 0.0001) (Figure 1). When par-
ticipants were divided into 4 groups according to
baseline CAC (CAC: 0, 0 to 100, >100 to 400, and
>400 Agatston units), a signiﬁcant graded cerebro-
vascular event-free survival rate was observed
TABLE 2 Occurrence of Cerebrovascular Events, Hemorrhagic Strokes,
Cerebral Infarcts, and TIAs
CAC Category
(Agatston Units) n
Cerebrovascular
Events
Hemorrhagic
Strokes
Cerebral
Infarcts TIAs
0 3,399 69 (2.0) 13 (0.4) 40 (1.2) 19 (0.6)
0–100 1,786 67 (3.8) 9 (0.5) 41 (2.3) 20 (1.1)
>100–400 923 52 (5.6) 4 (0.4) 36 (3.9) 15 (1.6)
>400 671 46 (6.9) 2 (0.3) 35 (5.2) 13 (1.9)
Total 234 28 152 67
Values are n (%). Events occurred within each CAC category after a mean of 9.5  2.4 years of follow-up in the
MESA cohort.
TIA ¼ transient ischemic attack; other abbreviations as in Table 1.
Time to Cerebrovascular Event (Days)
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Log rank chi-square = 59.84, p < 0.0001
0 1000 2000 3000
Number at Risk
CAC = 0 3399 3311 3154 3083 522
CAC > 0 3380 3217 2975 2786 402
CAC = 0 CAC > 0
FIGURE 1 Incident CVE in Subjects With and Without CAC
Kaplan-Meier analysis showing the event-free survival of participants with and without
coronary artery calcium (CAC) and incident cerebrovascular events (CVE) in the MESA
(Multi-Ethnic Study of Atherosclerosis) cohort.
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(Figure 2).
In (CAC þ 1) was a predictor for CVE, strokes, and
TIAs in both univariate and multivariable models
across sex and race/ethnic strata, except Chinese
(Table 3).
Table 4 shows univariate and multivariable hazard
ratios for cerebrovascular event, strokes, and TIAs
according to presence of CAC, stratiﬁed by sex and
race/ethnicity. The hazard ratio for females and all
race/ethnicities did not reach conventional statistical
signiﬁcance, although point estimates and directions
were similar to those in Table 2.
Coronary heart disease (CHD) is a known pre-
dictor of CVEs; thus, as a sensitivity analysis, we
excluded participants with incident CHD during the
follow-up examination (n ¼ 449). In (CAC þ 1) was a
predictor of CVE (n ¼ 205 events) in univariate and
full model (hazard ratio [HR]: 1.29 [95% conﬁdence
interval (CI): 1.22 to 1.36], p < 0.0001, and HR: 1.13
[95% CI: 1.06 to 1.20], p < 0.001, respectively), for
all strokes (n ¼ 153) (HR: 1.24 [95% CI: 1.16 to 1.31],
p < 0.001, and HR: 1.10 [95% CI: 1.03 to 1.18], p ¼
0.007, respectively), and TIAs (n ¼ 63) (HR: 1.26
[95% CI: 1.15 to 1.39], p < 0.001, and HR: 1.17 [95%
CI: 1.05 to 1.31], p ¼ 0.006, respectively) in this
subcohort. CAC (present/absent) also showed similar
associations with incident CVE, all strokes, and TIAs
in this subcohort (data not shown). The new ACC/
AHA recommended cutoff for improving risk as-
sessment using CAC ($300 Agatston units or $75
percentile for age, sex, and ethnicity) (8) was also
an independent predictor of CVE and strokes in this
cohort (for strokes HR: 3.02 [95% CI: 2.18 to 4.20],
p < 0.0001, and HR: 1.59 [95% CI: 1.11 to 2.27],
p ¼ 0.01, respectively).
There was signiﬁcant reduction in power when
the analysis was stratiﬁed by CAC categories: 0, 0
to 100, >100 to 400, and >400 Agatston units.
With CAC ¼ 0 as the reference, the univariate
and multivariable HRs in the Cox model were for
CAC 0 to 100: 1.38 (95% CI: 1.08 to 1.78), p ¼
0.01, and 1.19 (95% CI: 0.92 to 1.55), p ¼ 0.18; CAC
>100 to 400: 2.27 (95% CI: 1.16 to 4.47), p ¼ 0.08,
and 2.26 (95% CI: 1.11 to 4.57), p ¼ 0.02; and CAC
>400: 1.56 (95% CI: 0.97 to 2.52), p ¼ 0.06,
and 1.38 (95% CI: 0.81 to 2.36), p ¼ 0.23,
respectively.
In age-stratiﬁed analysis (by median age of 62
years), CAC was a predictor of CVE and strokes in
those greater than or equal to the median age in both
the univariate and multivariable Cox model. For
those below the median age (age <62 years), CAC was
a predictor of CVE and strokes in only univariateCox models but not in the multivariable Cox models
(data not shown).
Figure 3 shows the effect of CAC predic-
ting CVE across baseline Framingham stroke
risk (stratiﬁed by the median: 5.7%) in this MESA
cohort.
CAC AND CEREBROVASCULAR EVENT DISCRIMINATION.
For CVE (n ¼ 234), c-statistic for CAC (continuous)
alone was 0.642, and it was 0.744 in the full multi-
variable model without CAC. The addition of CAC
improved discrimination of our full multivariable
model (Table 3) by 0.011 (c-statistic: 0.744 vs. 0.755).
The c-statistic for the FSRS was 0.664. The addi-
tion of CAC improved its discrimination, as reﬂected
by a c-statistic of 0.706 (p < 0.01) (Figure 4). The
Time to Cerebrovascular Event (Days)
Su
rv
iv
al
 (%
)
100
95
90
0 1000 2000 3000
Number at Risk
CAC = 0 3399 3311 3154 3081 522
CAC 0 -100 1786 1709 1606 1525 248
CAC 100 - 400 923 891 819 765 97
CAC > 400 671 619 554 499 59
CAC = 0 CAC 0 -100 CAC 100 - 400 CAC > 400
Log rank test for trend chi-square = 95.79, p < 0.0001
FIGURE 2 Incident CVE by CAC Categories
Kaplan-Meier analysis showing the CVE event-free survival of participants with 0, 0 to
100, >100 to 400, and >400 CAC (Agatston units) and incident CVE in the MESA cohort.
Abbreviations as in Figure 1.
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1112c-statistic when constituents of the FSRS (risk factors)
were in the model was 0.721 and when CAC was
added to the model was 0.735 (data not shown).
For ischemic CVE (cerebral infarcts þ TIAs,
n ¼ 206), the c-statistic values related to CAC alone,
our full model (minus CAC), and the addition of
CAC to the full model were 0.657, 0.751, and 0.763
(p < 0.01), respectively. For cerebral infarcts (non-
TIA, nonhemorrhagic strokes) (n ¼ 152 events), these
values were 0.664, 0.767, and 0.777 (p < 0.01).TABLE 3 Predictive Value of Coronary Artery Calcium Score [In (CAC
Outcome Events, n
Univariate Model
Hazard Ratio (95% CI)
Cerebrovascular 234 1.28 (1.22–1.34)
All stroke 180 1.23 (1.17–1.31)
TIA 67 1.25 (1.14–1.37)
Sex stratiﬁed
Male 111 1.26 (1.17–1.37)
Female 123 1.32 (1.23–1.42)
Race/ethnicity stratiﬁed
Caucasian 93 1.32 (1.21–1.43)
Chinese 12 1.32 (1.04–1.67)
African American 69 1.24 (1.15–1.36)
Hispanic 60 1.33 (1.2–1.47)
Mean follow-up was 9.5  2.4 years. *Multivariable model was adjusted for age, se
pressure, total cholesterol, high-density lipoprotein, cigarette smoking status, blood pr
the follow-up period.
CI ¼ conﬁdence interval; other abbreviations as in Table 2.DISCUSSION
The goal of this study was to determine the predictive
value of CAC for incident CVE and to assess the
improvement in discrimination afforded by the
addition of CAC to known risk factors for CVE in a
multiethnic cohort. Our study, which is the largest
and has the longest follow-up so far, shows that
CAC is an independent predictor and improves the
discrimination for CVE.
Compared with other subclinical and novel
markers, CAC has been shown to be superior for
predicting, in the general population, CHD and car-
diovascular event composites, which include CVE
(4,5,14,16). The predictive value of CAC with regard to
CVE—which had been questionable before the present
study—was clearly shown in our study.
Unlike the HNR study, we did not observe that CAC
predicts stroke events in younger but not in older
adults. Furthermore, our results strongly suggest that
CAC improves the discrimination of incident CVE
above and beyond that related to known risk factors
and by a similar magnitude as the CHD risk prediction
in the MESA cohort (6).
CAC is a measure of atherosclerosis burden in the
coronary circulation (17). Atherosclerosis is a known
systemic disease that is almost always present in
other vascular beds once detected in the coronary
bed (18,19). Thus, observation of atherosclerosis in
the coronary bed suggests presence of atherosclerosis
in the cerebral circulation and elsewhere. However,
unlike CHD, the underlying pathophysiology, which
is mainly atherosclerosis, cerebrovascular disease/
events have a more heterogeneous pathophysiology
(20), including hemorrhage, small-vessel lacunarþ1)] for Incident Cerebrovascular Events in the MESA Cohort
p Value
Multivariable Model*
Hazard Ratio (95% CI) p Value
<0.0001 1.13 (1.07–1.20) <0.0001
<0.0001 1.10 (1.03–1.18) 0.003
<0.0001 1.16 (1.04–1.31) 0.007
<0.0001 1.15 (1.05–1.24) 0.001
<0.0001 1.11 (1.03–1.21) 0.010
<0.0001 1.14 (1.03–1.25) 0.008
0.02 1.18 (0.89–1.56) 0.25
<0.0001 1.14 (1.02–1.26) 0.016
<0.0001 1.14 (1.01–1.28) 0.036
x, race/ethnicity, body mass index, diabetes mellitus, systolic and diastolic blood
essure medication use, statin use, and interim atrial ﬁbrillation that occurred during
TABLE 4 Predictive Value of Coronary Artery Calcium (Present vs. Absent) for Incident Cerebrovascular Events in the MESA Cohort
Outcome Events, n
Univariate Model
Hazard Ratio (95% CI) p Value
Multivariable Model*
Hazard Ratio (95% CI) p Value
Cerebrovascular 234 2.88 (2.18–3.82) <0.0001 1.13 (1.07–1.20) <0.0001
Stroke 180 2.57 (1.86–3.55) <0.0001 1.45 (1.01–2.07) 0.043
TIA 67 2.71 (1.59–4.61) 0.0002 1.81 (1.00–3.27) 0.049
Sex stratiﬁed
Male 111 3.02 (1.88–4.81) <0.0001 1.84 (1.11–3.05) 0.018
Female 123 2.95 (2.05–4.25) <0.0001 1.33 (0.88–2.00) 0.174
Race/ethnicity stratiﬁed
Caucasian 93 3.41 (2.08–5.60) <0.0001 1.65 (0.95–2.89) 0.075
Chinese 12 2.74 (0.82–9.17) 0.10 1.57 (0.40–6.12) 0.513
African American 69 2.35 (1.45–3.83) 0.0005 1.53 (0.89–2.63) 0.123
Hispanic 60 3.71 (2.14–6.47) <0.0001 1.79 (0.96–3.34) 0.061
Mean follow-up was 9.5  2.4 years. *Multivariable model was adjusted for age, sex, race/ethnicity, body mass index, diabetes mellitus, systolic and diastolic blood
pressure, total cholesterol, high-density lipoprotein, cigarette smoking status, blood pressure medication use, statin use, and interim atrial ﬁbrillation that occurred during
the follow-up period.
Abbreviations as in Table 2.
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FIGURE 3 CAC Predicting CVE by Global Risk
Plot of incident CVE rates within CAC categories (CAC ¼ 0 [1st], CAC ¼ 0 to
100 [2nd], CAC ¼ 101 to 400 [3rd], and CAC > 400 Agatston units) across the
median Framingham stroke risk score (FSRS) in MESA participants after 9.5
years of follow-up. Abbreviations as in Figure 1.
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1113strokes, and ischemia. The heterogeneous patho-
physiology of cerebrovascular disease/events makes
predicting events using a single marker such as
CAC in 1 of the pathophysiologic pathways unappeal-
ing. However, as evident from the present study
and others, most cerebrovascular disease/events
(approximately 85%, 152 of 180 strokes) are due to
cerebral infarcts (21). With a few exceptions, such as
cerebral infarcts from cardioembolic source, most of
these cerebral infarcts may be due to in situ ath-
erosclerosis, small-vessel disease including micro-
atheroma, or embolism of plaques from extracranial
vesselsor theaorta; for all of these,CACwouldbeagood
surrogate marker. Thus, despite the heterogeneous
pathophysiology of cerebrovascular disease, CAC as
a measure of atherosclerotic burden in the coronary
bed can still be a good predictor and can be used
to identify most subjects at risk for aggressive preven-
tive therapy, such as statins.
Epidemiological and observational studies have
shown a clear association between hypertension and
incident CVE, suggesting that blood pressure control
may be a good target for primary stroke prevention
(22,23). Primary stroke prevention trials with upstream
modiﬁcation of blood pressure have shown a signi-
ﬁcant reduction in incident CVE (24–26). However,
current data on the association between dyslipidemia
and incident CVE are mixed (27–30). To date, no clin-
ical trial data exist on the effects of lipid-lowering
therapy on CVEs in asymptomatic individuals. How-
ever, a secondary analysis of primary prevention
trials and long-term clinical trials, which evaluated
CVE as a secondary outcome in patients with estab-
lished coronary heart disease, showed a reductionin CVEs with statin therapy (31–35). Thus, CAC, a
noninvasive test, can identify individuals for statin
therapy with asymptomatic CHD but at high risk for
CVE. Clinical trials primarily evaluating the effect
of statins on CVEs in individuals without clinical
cardiovascular disease but positive CAC are needed.
Although our study shows an improvement in
discrimination by CAC over current risk factors, we
caution the incorporation of CAC into primary
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FIGURE 4 Predictive Accuracy of CAC, FSRS, and CAC þ FSRS
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as in Figures 1 and 3.
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1114stroke prevention strategies until concerns about
ionizing radiation exposure (w1 mSv) are weighed
and this approach has been deemed cost-effective.
Our results also need to be replicated in other
cohorts.
STUDY LIMITATIONS. The strengths of our study
include its large sample size, multiethnic co-
hort, relatively long follow-up, and the use of adju-
dicated CVE. The limitations include the relatively
small number of CVE, which limited our ability to
make deﬁnitive inferences in subgroups formed by
sex and race/ethnicity. MESA is an observational
study, and thus, residual confounding may haveinﬂuenced our results. MESA does not include other
ethnic groups, such as American Indians, or Asian
groups other than Chinese. In addition, the propor-
tion of each ethnic group in MESA does not accurately
reﬂect that of the U.S. population. Although our pri-
mary outcome, CVE, and its constituents were adju-
dicated, atrial ﬁbrillations that occurred during
follow-up were a combination of adjudicated; Inter-
national Classiﬁcation of Diseases, Ninth Revision
code-derived; and self-reports. The FSRS includes
prior CVD and atrial ﬁbrillation and was derived for
stroke prediction in individuals with and without
these comorbidities. MESA participants were free of
CVD and atrial ﬁbrillation at baseline but should not
affect the discriminative ability of the FSRS in this
cohort (asymptomatic multiethnic cohort). Last,
because the present study involved individuals
without clinical cardiovascular disease at baseline,
our results may not be applicable to other
populations.
CONCLUSIONS
CAC was found to be an independent predictor of
CVE, strokes, and TIAs in a large multiethnic cohort.
CAC also seems to have improved prediction over
known risk factors for CVE, including atrial ﬁbrilla-
tion and the FSRS.
ACKNOWLEDGMENTS The authors thank the in-
vestigators, staff, and participants of the MESA
study for their valuable contributions. A full list of
participating MESA investigators and institutions
can be found at http://www.mesa-nhlbi.org. The
authors also thank Karen P. Klein, MS, for editing this
paper.
REPRINT REQUESTS AND CORRESPONDENCE: Dr.
Joseph Yeboah, Heart and Vascular Center of Excel-
lence, Wake Forest University School of Medicine,
Medical Center Boulevard, Winston-Salem, North
Carolina 27157. E-mail: jyeboah@wakehealth.edu.RE F E RENCE S1. NewmanAB,NaydeckBL, IvesDG, et al. Coronary
artery calcium, carotid artery wall thickness, and
cardiovascular disease outcomes in adults 70 to 99
years old. Am J Cardiol 2008;101:186–92.
2. Folsom AR, Kronmal RA, Detrano RC, et al. Coro-
nary artery calciﬁcation comparedwith carotid intima
media thickness in the prediction of cardiovascular
disease incidence: the Multi-Ethnic Study of Athero-
sclerosis (MESA). Arch InternMed 2008;168:1333–9.
3. Elias-Smale SE, Wieberdink RG, Odink AE, et al.
Burden of atherosclerosis improves the predictionof coronary heart disease but not cerebrovascular
events: the Rotterdam Study. Eur Heart J 2011;32:
2050–8.
4. Yeboah J, McClelland RL, Polonsky TS, et al.
Comparison of novel risk markers for improvement
in cardiovascular risk assessment in intermediate
risk individuals. JAMA 2012;308:788–95.
5. Kavousi M, Elias-Smale S, Rutten JH, et al.
Evaluation of newer risk markers for coronary
heart disease risk classiﬁcation: a cohort study.
Ann Intern Med 2012;156:438–44.6. Polonsky TS, McClelland RL, Jorgensen NW,
et al. Coronary artery calcium score and risk clas-
siﬁcation for coronary heart disease prediction.
JAMA 2010;303:1610–6.
7. Kavousi M, Leening MJG, Witterman JCM.
Markers for prediction of cardiovascular risk. JAMA
2012;308:2561–2.
8. Goff DC Jr., Lloyd-Jones DM, Bennett G,
et al. 2013 ACC/AHA guideline on the assess-
ment of cardiovascular risk: a report of the
American College of Cardiology/American Heart
J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . 7 , N O . 1 1 , 2 0 1 4 Gibson et al.
N O V E M B E R 2 0 1 4 : 1 1 0 8 – 1 5 CAC Predicts Strokes
1115Association Task Force on Practice Guidelines.
J Am Coll Cardiol 2014;63:2935–59.
9. D’Agostino RB Sr., Grundy S, Sullivan LM,
Wilson P, CHD Risk Prediction Group. Validation of
the Framingham coronary heart disease prediction
scores: results of a multiple ethnic groups inves-
tigation. JAMA 2001;286:180–7.
10. Hermann DM, Gronewold J, Lehmann N, et al.,
Heinz Nixdorf Recall Study Investigative Group.
Coronary artery calciﬁcation is an independent
stroke predictor in the general population. Stroke
2013;44:1008–13.
11. Bild DE, Bluemke DA, Burke GL, et al. Multi-
Ethnic Study of Atherosclerosis: objectives and
design. Am J Epidemiol 2002;156:871–81.
12. Friedewald WT, Levy RI, Fredrickson DS. Esti-
mation of the concentration of low-density lipo-
protein cholesterol in plasma, without use of the
preparative ultracentrifuge. Clin Chem 1972;18:
499–502.
13. Carr JJ, Nelson JC, Wong ND, et al. Calciﬁed
coronary artery plaque measurement with cardiac
CT in population-based studies: standardized
protocol of Multi-Ethnic Study of Atherosclerosis
(MESA) and Coronary Artery Risk Development in
Young Adults (CARDIA) study. Radiology 2005;
234:35–43.
14. Agatston AS, Janowitz WR, Hildner FJ,
Zusmer NR, Viamonte M Jr., Detrano R. Quantiﬁ-
cation of coronary artery calcium using ultrafast
computed tomography. J Am Coll Cardiol 1990;15:
827–32.
15. D’Agostino RB, Wolf PA, Belenger AJ,
Kannel WB. Stroke risk proﬁle. Adjustment for
antihypertensive medications: The Framingham
Heart Study. Stroke 1994;25:40–3.
16. Hlatky MA. Framework for evaluating novel
risk markers. Ann Intern Med 2012;156:468–9.
17. Simons DB, Schwartz RS, Edwards WD,
Sheedy PF, Breen JF. Non-invasive deﬁnition of
anatomic coronary disease by ultrafast computed
tomography: a quantitative pathologic comparison
study. J Am Coll Cardiol 1992;20:1118–26.18. Lahoz C, Carlos JM III. Atherosclerosis as a
systemic disease. Rev Esp Cardiol 2007;60:
184–95.
19. Tison GH, Blaha MJ, Nasir K. Atherosclerosis
imaging in multiple vascular beds—enough het-
erogeneity to improve risk prediction? Athero-
sclerosis 2011;214:261–3.
20. Mohr JP, Albers GW, Amarenco P, et al.
Etiology of stroke. Stroke 1997;28:1501–6.
21. Go AS, Mozaffarian D, Roger VL, et al., Amer-
ican Heart Association Statistics Committee and
Stroke Statistics Subcommittee. Heart disease and
stroke statistics—2013 update: a report from the
American Heart Association. Circulation 2013;127:
e6–245.
22. Chobanian AV, Bakris GL, Black HR, et al. The
seventh report of the Joint National Committee
on Prevention, Detection, Evaluation, and Treat-
ment of High Blood Pressure: the JNC 7 report.
JAMA 2003;289:2560–72.
23. Whelton PK, He J, Appel LJ, et al. Primary
prevention of hypertension: clinical and public
health advisory from the National High Blood
Pressure Education Program. JAMA 2002;288:
1882–8.
24. Psaty BM, Lumley T, Furberg CD,
SchellenbaumG, PahorM, AldermanMH,Weiss NS.
Health outcomes associated with various antihy-
pertensive therapies used as ﬁrst-line agents: a
network meta-analysis. JAMA 2003;289:2534–44.
25. Turnbull F. Effects of different blood-
pressure-lowering regimens on major cardiovas-
cular events: results of prospectively-designed
overviews of randomized trials. Lancet 2003;
362:1527–35.
26. Law MR, Morris JK, Wald NJ. Use of blood
pressure lowering drugs in the prevention of car-
diovascular disease: meta-analysis of 147 ran-
domized trials in the context of expectations from
prospective epidemiological studies. BMJ 2009;
338:b1665.
27. Horenstein RB, Smith DE, Mosca L. Cholesterol
predicts stroke mortality in the Women’s Pooling
Project. Stroke 2002;33:1863–8.28. Kurth T, Everett BM, Buring JE, Kase CS,
Ridker PM, Gaziano JM. Lipid levels and the risk of
ischemic stroke in women. Neurology 2007;68:
556–62.
29. Shahar E, Chambless LE, Rosamond WD, et al.
Plasma lipid proﬁle and incident ischemic stroke:
the Atherosclerosis Risk in Communities (ARIC)
study. Stroke 2003;34:623–31.
30. Bots ML, Elwood PC, Nikitin Y, et al. Total and
HDL cholesterol and risk of stroke. EUROSTROKE:
a collaborative study among research centers in
Europe. J Epidemiol Community Health 2002;56:
i19–24.
31. Amarenco P, Labreuche J, Lavallee P,
Touboul PJ. Statins in stroke prevention and
carotid atherosclerosis: systematic review and up-
to-date meta-analysis. Stroke 2004;35:2902–9.
32. Baigent C, Keech A, Kearney PM, et al. Efﬁcacy
and safety of cholesterol-lowering treatment:
prospective meta-analysis of data from 90,056
participants in 14 randomized trials of statins.
Lancet 2005;366:1267–78.
33. Amarenco P, Labreuche J. Lipid management
in the prevention of stroke: review and updated
meta-analysis of statins for stroke prevention.
Lancet Neurol 2009;8:453–63.
34. Sever PS, Dahlöf B, Poulter NR, et al., ASCOT
Investigators. Prevention of coronary and stroke
events with atorvastatin in hypertensive patients
who have average or lower-than-average choles-
terol concentrations, in the Anglo-Scandinavian
Cardiac Outcomes Trial–Lipid Lowering Arm
(ASCOT-LLA): a multicentre randomized
controlled trial. Lancet 2003;361:1149–58.
35. EverettBM,GlynnRJ,MacFadyenJG,RidkerPM.
Rosuvastatin in the prevention of strokes among
men and women with elevated C-reactive protein:
Justiﬁcation for Use of Statins in Prevention:
an Intervention Trial Evaluating Rosuvastatin
(JUPITER). Circulation 2010;121:143–50.
KEY WORDS cerebrovascular disease,
coronary artery calcium score,
risk prediction, prevention
